- Home
- MIRM vs XENE Comparison
MIRM vs XENE Comparison
Compare MIRM & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | XENE |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.3B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIRM | XENE |
|---|---|---|
| Price | $106.24 | $55.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $119.85 | $68.55 |
| AVG Volume (30 Days) | 667.9K | ★ 782.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | $311,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | $2,496.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.89 | $28.19 |
| 52 Week High | $112.00 | $62.91 |
Technical Indicators
Market Signals| Indicator | MIRM | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 46.00 |
| Support Level | $87.26 | $52.92 |
| Resistance Level | $107.51 | $56.66 |
| Average True Range (ATR) | 5.87 | 1.99 |
| MACD | 0.98 | -0.28 |
| Stochastic Oscillator | 75.13 | 35.37 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.